Literature DB >> 12450952

A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder.

Abraham Reichenberg1, Mark Weiser, Jonathan Rabinowitz, Asaf Caspi, James Schmeidler, Mordechai Mark, Zeev Kaplan, Michael Davidson.   

Abstract

OBJECTIVE: The premorbid intellectual, language, and behavioral functioning of patients hospitalized for schizophrenia, schizoaffective disorder, or nonpsychotic bipolar disorder was compared with that of healthy comparison subjects.
METHOD: The Israeli Draft Board Registry, which contains measures of intellectual, language, and behavioral functioning for the unselected population of 16- to 17-year-olds, was merged with the National Psychiatric Hospitalization Case Registry, which contains diagnoses for all patients with psychiatric hospitalizations in Israel. The database was used to identify adolescents with no evidence of illness at their draft board assessment who were later hospitalized for nonpsychotic bipolar disorder (N=68), schizoaffective disorder (N=31), or schizophrenia (N=536). The premorbid functioning of these subjects was compared to that of nonhospitalized individuals matched for age, gender, and school attended at the time of the draft board assessment. The diagnostic groups of hospitalized subjects were also compared.
RESULTS: Relative to the comparison subjects, subjects with schizophrenia showed significant premorbid deficits on all intellectual and behavioral measures and on measures of reading and reading comprehension. Subjects with schizophrenia performed significantly worse on these measures than those with a nonpsychotic bipolar disorder, who did not differ significantly from the comparison subjects on any measure. Subjects with schizoaffective disorder performed significantly worse than the comparison subjects only on the measure of nonverbal abstract reasoning and visual-spatial problem solving and performed significantly worse than subjects with nonpsychotic bipolar disorder on three of the four intellectual measures and on the reading and reading comprehension tests.
CONCLUSIONS: The results support a nosologic distinction between nonpsychotic bipolar disease and schizophrenia in hospitalized patients.

Entities:  

Mesh:

Year:  2002        PMID: 12450952     DOI: 10.1176/appi.ajp.159.12.2027

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  87 in total

1.  Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.

Authors:  Axel Krug; Valentin Markov; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Markus M Nöthen; Alexander Georgi; Jana Strohmaier; Marcella Rietschel; Tilo Kircher
Journal:  Hum Brain Mapp       Date:  2011-01       Impact factor: 5.038

Review 2.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

Review 3.  Neurocognitive function as an endophenotype for genetic studies of bipolar affective disorder.

Authors:  Jonathan B Savitz; Mark Solms; Rajkumar S Ramesar
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 4.  [Early recognition and intervention for schizophrenia].

Authors:  N Mossaheb; G Wiesegger; G P Amminger; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

Review 5.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

6.  MATRICS cognitive consensus battery (MCCB) performance in children, adolescents, and young adults.

Authors:  George C Nitzburg; Pamela Derosse; Katherine E Burdick; Bart D Peters; Chaya B Gopin; Anil K Malhotra
Journal:  Schizophr Res       Date:  2013-12-08       Impact factor: 4.939

7.  Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.

Authors:  Max Lam; W David Hill; Joey W Trampush; Jin Yu; Emma Knowles; Gail Davies; Eli Stahl; Laura Huckins; David C Liewald; Srdjan Djurovic; Ingrid Melle; Kjetil Sundet; Andrea Christoforou; Ivar Reinvang; Pamela DeRosse; Astri J Lundervold; Vidar M Steen; Thomas Espeseth; Katri Räikkönen; Elisabeth Widen; Aarno Palotie; Johan G Eriksson; Ina Giegling; Bettina Konte; Annette M Hartmann; Panos Roussos; Stella Giakoumaki; Katherine E Burdick; Antony Payton; William Ollier; Ornit Chiba-Falek; Deborah K Attix; Anna C Need; Elizabeth T Cirulli; Aristotle N Voineskos; Nikos C Stefanis; Dimitrios Avramopoulos; Alex Hatzimanolis; Dan E Arking; Nikolaos Smyrnis; Robert M Bilder; Nelson A Freimer; Tyrone D Cannon; Edythe London; Russell A Poldrack; Fred W Sabb; Eliza Congdon; Emily Drabant Conley; Matthew A Scult; Dwight Dickinson; Richard E Straub; Gary Donohoe; Derek Morris; Aiden Corvin; Michael Gill; Ahmad R Hariri; Daniel R Weinberger; Neil Pendleton; Panos Bitsios; Dan Rujescu; Jari Lahti; Stephanie Le Hellard; Matthew C Keller; Ole A Andreassen; Ian J Deary; David C Glahn; Anil K Malhotra; Todd Lencz
Journal:  Am J Hum Genet       Date:  2019-08-01       Impact factor: 11.025

8.  DTNBP1 genotype influences cognitive decline in schizophrenia.

Authors:  Katherine E Burdick; Terry E Goldberg; Birgit Funke; John A Bates; Todd Lencz; Raju Kucherlapati; Anil K Malhotra
Journal:  Schizophr Res       Date:  2006-10-30       Impact factor: 4.939

9.  Clinical implications of cognitive function in bipolar disorder.

Authors:  C T Sudhir Kumar; Sophia Frangou
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

10.  Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia.

Authors:  Daniel N Allen; Gregory P Strauss; Kimberly A Barchard; Mary Vertinski; William T Carpenter; Robert W Buchanan
Journal:  Schizophr Res       Date:  2013-03-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.